The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Unraveling relatlimab (RELA)-specific biology: Biomarker analyses in patients (pts) with metastatic non-small cell lung cancer (mNSCLC) treated with 1L nivolumab (NIVO) + RELA high-dose (HD) and platinum-doublet chemotherapy (PDCT).
 
Martin Reck
Consulting or Advisory Role - Abbvie; Amgen; AstraZeneca; BioNTech SE; Boehringer Ingelheim; Bristol-Myers Squibb; Daiichi Sankyo Europe GmbH; GlaxoSmithKline K.K.; IO Biotech; IO Biotech; Lilly; Merck Serono; Mirati Therapeutics; MSD Oncology; Novartis; Pfizer; Roche/Genentech; Samsung Bioepis; Sanofi/Regeneron
Speakers' Bureau - Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Lilly; Merck Serono; Mirati Therapeutics; MSD Oncology; Novartis; Pfizer; Roche/Genentech; Sanofi/Aventis
(OPTIONAL) Uncompensated Relationships - “Medical writing assistance for this abstract was provided by Bena Lim, PhD, CMPP, of Nucleus Global, an Inizio Company, and funded by F. Hoffmann-La Roche Ltd.” (Inst); “Medical writing assistance for this abstract was provided by Nimisha H. Bhoola, PhD, of Nucleus Global, an Inizio Company, and funded by F. Hoffmann-La Roche Ltd.” (Inst)
 
Jaclyn Neely
Employment - Bristol-Myers Squibb
Stock and Other Ownership Interests - Bristol-Myers Squibb
 
Vamsidhar Velcheti
Honoraria - Galvanize Therapeutics
Consulting or Advisory Role - Amgen; AstraZeneca/MedImmune; Bristol-Myers Squibb; GlaxoSmithKline; Janssen Oncology; Merck; Novocure; Picture Health; Regeneron; Taiho Oncology; Takeda
Research Funding - Alkermes (Inst); Altor BioScience (Inst); Atreca (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst); Genentech (Inst); Genoptix (Inst); GlaxoSmithKline (Inst); Heat Biologics (Inst); Leap Therapeutics (Inst); Merck (Inst); NantWorks (Inst); OncoPlex Diagnostics (Inst); RSIP Vision (Inst); Trovagene (Inst)
 
Sheida Hayati
Employment - Bristol-Myers Squibb
Stock and Other Ownership Interests - Bristol-Myers Squibb
 
Annie Yu
Employment - Bristol-Myers Squibb/Celgene
Stock and Other Ownership Interests - Bristol-Myers Squibb/Celgene
 
Korey Demers
Employment - Bristol Myers Squibb
Stock and Other Ownership Interests - Bristol Myers Squibb
 
Michael Schenker
Research Funding - Abbvie; Amgen; Astellas Pharma; AstraZeneca; BeiGene; BIOVEN; Bristol-Myers Squibb; Clovis Oncology; Daiichi Sankyo Europe GmbH; Eisai; Five Prime Therapeutics; Gilead Sciences; GlaxoSmithKline; Lilly; MSD; Mylan; Novartis; Pfizer/EMD Serono; PharmaMar; Regeneron; Roche; Samsung Healthcare; Sanofi/Regeneron; Tesaro
Travel, Accommodations, Expenses - Bristol Myers Squibb; Pfizer
 
Manuel Cobo
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Janssen; Kyowa Kirin International; Lilly; MSD; Novartis; Pfizer; Roche; Sanofi; Takeda
Speakers' Bureau - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Janssen; Kyowa Kirin International; Lilly; MSD; Novartis; Novocure; Pierre Fabre; Roche; Sanofi; Takeda
 
Mauricio Burotto
Consulting or Advisory Role - BMS; MSD Oncology; Roche/Genentech
Speakers' Bureau - AstraZeneca; BMS
Travel, Accommodations, Expenses - BMSi; BMSi
 
Francisco Orlandi
Honoraria - AstraZeneca; Roche/Genentech
Consulting or Advisory Role - AstraZeneca (Inst); Bristol-Myers Squibb; Bristol-Myers Squibb (Inst); MSD Oncology; Pfizer
Speakers' Bureau - AstraZeneca/MedImmune; Roche
Research Funding - Amgen; Astellas Medivation; AstraZeneca/MedImmune; Bristol-Myers Squibb (Inst); Daiichi-Sankyo (Inst); Genentech/Roche; Gilead Sciences (Inst); GlaxoSmithKline (Inst); mAbxience; MSD Oncology; Pfizer; PharmaMar (Inst); Regeneron (Inst)
Travel, Accommodations, Expenses - Genentech/Roche; MSD Oncology
 
Priyanka Kasbekar
Employment - Bristol Myers Squibb
 
Anila Qureshi
Employment - Bristol Myers Squibb
Stock and Other Ownership Interests - Bristol Myers Squibb
 
Charlie Garnett-Benson
Employment - Bristol Myers Squibb
Stock and Other Ownership Interests - Bristol Myers Squibb
Patents, Royalties, Other Intellectual Property - FGL1 as a biomarker for LAG-3 targeting regimens in oncology patent application submitted.
Travel, Accommodations, Expenses - Bristol Myers Squibb
 
Nicolas Girard
Employment - AstraZeneca (I)
Consulting or Advisory Role - Abbvie; AMGEN; AstraZeneca; BeiGene; Bristol-Myers Squibb; Daiichi Sankyo/Astra Zeneca; Gilead Sciences; Ipsen; Janssen; LEO Pharma; Lilly; MSD; Novartis; Pfizer; Roche; Sanofi; Takeda
Research Funding - AstraZeneca (Inst); BMS (Inst); MSDavenir (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Janssen Oncology; Janssen Oncology; Roche